Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576909 | 0.92 | PKM (0.43) | PKMACHEHTTTDP1TSHR | |
| SCHEMBL4851706 | 0.92 | PKM (0.46) | PKMACHEHTTTDP1ALDH1A1 | |
| SCHEMBL4862327 | 0.90 | PKM (0.50) | PKMACHEHTTTDP1ALDH1A1 | |
| SCHEMBL4859871 | 0.90 | PKM (0.43) | PKMACHEHTTTDP1TSHR | |
| SCHEMBL5576944 | 0.87 | ACHE (0.39) | PKMACHEHTTTDP1PTGES2 | |
| SCHEMBL4852122 | 0.87 | NPSR1 (0.53) | PKMACHETDP1TSHRALDH1A1 | |
| SCHEMBL4860428 | 0.84 | CTNNB1 (0.40) | PKMACHETDP1ALDH1A1PTGES2 | |
| SCHEMBL4858874 | 0.84 | ACHE (0.38) | PKMACHEALDH1A1PTGES2AOC3 | |
| SCHEMBL5313256 | 0.84 | PKM (0.39) | PKMACHEHTTTDP1TSHR | |
| SCHEMBL4855322 | 0.83 | ALDH1A1 (0.44) | ACHEALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | PKM 3404/4885ACHE 1/4885HTT 3012/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | PKM 3404/4885ACHE 1/4885HTT 3012/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | PKM 3713/4885ACHE 1/4885HTT 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.